[13C6]-Doravirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It is a modified form of Doravirine, a drug approved by the FDA in 2018 for use in combination with other antiretroviral agents in adults with HIV-1 infection who have no prior antiretroviral treatment history.
[13C6]-Doravirine contains six carbon-13 isotopes, which can be used in pharmacokinetic studies to analyze drug metabolism, absorption, and distribution in the body. This is because the presence of carbon-13 isotopes allows for the differentiation of [13C6]-Doravirine from other forms of Doravirine in biological samples, such as blood or urine.
The chemical structure of [13C6]-Doravirine consists of a benzoxazole ring, a pyridine ring, and a cyclopropylamine moiety. It works by binding to the reverse transcriptase enzyme, which is essential for the replication of HIV-1, and inhibiting its activity. This prevents the virus from multiplying and spreading throughout the body, thus reducing the viral load and slowing the progression of HIV-1 infection.
Clinical trials have shown that [13C6]-Doravirine is effective in reducing HIV-1 viral load and increasing CD4 cell counts in patients with HIV-1 infection. It is typically administered orally, once daily, and can be taken with or without food. As with any medication, [13C6]-Doravirine may cause side effects, such as headache, nausea, and fatigue, and should only be used under the supervision of a healthcare provider.